Share Name Share Symbol Market Type Share ISIN Share Description
Benchmark Holdings LSE:BMK London Ordinary Share GB00BGHPT808 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50p -1.23% 40.00p 39.00p 41.00p 40.50p 39.75p 40.50p 11,500 14:00:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 109.4 -22.4 -4.4 - 208.95

Benchmark Holdings Share Discussion Threads

Showing 501 to 525 of 525 messages
Chat Pages: 21  20  19  18  17  16  15  14  13  12  11  10  Older
They bought around them with no regard for making profit up to now. I was in them in the 60's, but the profits forecasts and their performance did not make sense for me to hold. They need to bed everything down, I think there are some efficiencies to make, stop the acquisitions and prove themselves.
Exbroker - Agreed -still trying to come to a decision as to whether the problems are with the product or management. So this is why I am watching and waiting. If the latter then then they can be removed and a new bunch installed. If the product new formulation and costings but always very much harder to find buyers the 2nd time round.
Hi Pugugly I have been in since the start and have supported the fund raises as well, so am losing big time. I would like them to stick to what they now have and make a profit and generate some cash, simple but so far, they have managed not to do this very well. There comes a point when one of the industry big boys just hoovers them up but I am not sure it is yet!
Continuing to fall - no 40/42 p/e still far too high - Any thoughts as to where it has to fall to have gamble value ???
Oh dear - came to have a look as at a 1 year low and falling - Look who is a major shareholder Significant shareholders % of issued share capital Woodford Investment Management LLP 25.10 With his current record a possible red flag ???????????????????????
Buy note out from Kepler Cheuvreux this am. Target price 68p. One thing that I noted is that the total market cap at £230m is now pretty much what they paid to acquire Inve back in Dec 2015! ---------------------------------------------- With FY trading in line and assuming a 65% YOY recovery in EBITDA in fiscal 2018E, the share price has overreacted. We therefore upgrade our rating to Buy. This remains a high-risk, high-return investment case: Benchmark combines a lack of focus and capital discipline, with a unique growth portfolio exposed to high value added, early life stages of fish. FY trading update: no further deterioration FY trading indicated for EBITDA of GBP8.7-9.3m for fiscal 2017, versus our GBP9.2m. This implies that H2 results did not deteriorate further after a disappointing H1. H2 trends were broadly in line with expectations, including ongoing strong performance in Breeding & Genetics. Animal Health continued to see operational losses in H2, due to lower sales in Salmosan and investments in new products, but we assume these to be less severe than in H1. Also, WC and capex were under control. Upgrade from Hold to Buy We upgrade the stock from Hold to Buy. The share price has more than halved since January. We believe that current valuation levels have more than factored in the operational setbacks in fiscal 2017, as the trading update indicates that downside to our estimates for 2017/18 is limited. Moreover: 1) we project EBITDA to increase by 65% YOY in 2018E, with consensus assuming an increase of 100% YOY; and 2) prospects for the key AAN division (55% of group sales) have improved, as the worst in global shrimp production seems to be over. This is largely driven by strong growth in Ecuador and India, while production in China and Thailand is still under pressure, due to diseases and adverse weather conditions. Still we perceive that global shrimp output might grow by low-to-mid single digits in 2018, whereas the recent contract renewal with the GSL-Coop provides stability. TP and key risks The share price has proven be very volatile since 2015, which we believe is a reflection of low earnings visibility and the unrestrained expansion into new products and territories. We lower our TP by 8% to 68p by applying a slightly higher WACC of 9%, with our long-term growth rate still at 5%. Do note that our TP does not include the NPV of the product pipeline, which we estimate at 65p per share. The key risks to our investment case relate to: 1) a further broadening of the portfolio into new products, services and territories, whereas we prefer to see proof of success of all the existing initiatives first, before entering into new adventures; and 2) higher-than expected investment and start-up costs for new product introductions.
Got any salmon?
Market cap to still far too high (imo) "adjusted EBITDA to be in the range GBP8.7m to GBP9.3m, for the full year." & what will be in the "adjustments!!" Agree re 30's - Looks as though will have to run hard to meet Numis target unless new products VERY successful - but in my experience many new products have teething problems - Classic example another of Woodford's duds - RM2 and fibreglass pallets.
Another Woodford clanger, loving it though as Woodford legions of Daily Mail fans get a good rinsing.
my retirement fund
Hmmmm, I'm certainly not buying back in on that TU. Not bad per se, but has a warning stitched in the lining IMO, & "share price down into the 30's is feasible" indeed if they need to wait before getting sales of their anti sea-lice product.
napoleon 14th
What's fair value? Numis forecast it to do c.£11m PBT to 9/19. Market cap now £269m. Probably got some debt now, not sure how much. Give them 15x 11m = £165m market cap. So share price down into the 30's is feasible unless they start meeting their numbers and upgrading forecasts. They might want to consolidate the share so it doesn't look like a penny dribbler.
simon gordon
What's up with this one? I used to hold & sold, thank my lucky stars, at c.90p. Chart since then looks a nightmare!
napoleon 14th
We will be hosting a results webinar with the management of Benchmark Holdings on Thursday 29th June at 11.45am. The presentation will last around 30mins with time afterwards for Q&A. If you would like to send questions in ahead of the webinar please send them to To register for free and find out more please visit:
Bit of a neutral TS, eh? "In line" didn't impress, obviously! IMO the risk is disease, the reward is sales of treatments, if these happen. Anyhow, I took the +33% I have here & on to pastures new.
napoleon 14th
Good to see BMK moving close to the £1 mark once again :) To recap - recent NED and II activity.... NED Alex Hambro buying circa 53k shares at 90p yesterday NED Kevin Quinn bought 25k @ 94p in Feb A few big trades in the last few months 1m + 600k at 109.5p towards end Jan FERD adding another 20m shares at 97p (this Norwegian fund now holds about 16%) 75.83% of the shares are not in public hands with Woodford holding about 25% ...tells a story/paints a picture....if people are listening/watching as coming events cast their shadow before. Good luck all :)
Another excellent contract with one the world leaders in salmon production.... RNS Non-Regulatory 7 March 2017 Benchmark Holdings plc ("Benchmark" or the "Company") Contract win for Benchmark Benchmark announces today that it has signed a long-term agreement with SalMar ASA ("SalMar") to provide genetics, health and knowledge services to the company. The full suite of services the Company is providing illustrates Benchmark's leading position in the market, as well as its ability to offer a wide spread of products and solutions across the salmon's life cycle. SalMar is one of world's leading salmon producers. Benchmark will, through it's subsidiary SalmoBreed AS, form a 50/50 joint venture for the production of SalMar's salmon strain, Rauma. This joint venture to be called 'SalMar Genetic AS', will be formed by a demerger of SalMar's salmon production facility in Reistad, Norway. Benchmark will take full responsibility for managing the breeding programme through its subsidiary Akvaforsk Genetics Center AS. The agreement also includes sales of eggs from Benchmark's land based sites in Iceland and once commissioned from its Salten site in Norway. The Benchmark group will also provide fish health services, diagnostics, and health products. Malcolm Pye, CEO of Benchmark, said; "We are delighted to sign an agreement with such a blue-chip partner in the salmon market. It is testament to our customers' recognition of the benefits of our growing, integrated package of products and services, as well as our ability to enhance value for producers and contribute towards the overall sustainability of the aquaculture industry."
Ferd add another 20m shares at 97p to take their stake over 16%....clearly the Norwegians seem to like their Benchmark salmon amongst other treats BMK has to offer. Big vote of confidence, not that it was needed !
Good to see a big Norwegian player increase their stake to 12.8%
Good to see Non Exec Kevin Quinn RNS of 25k buy shares @ circa 94p yesterday.....
Aha Janeann - we meet again ! I thought our investing styles were similar so I guess our paths cross frequently and I am pleased that we are doing well (atleast for now in a bull market). BMK is another of my decent sized holds - I think that the company has developed a great IP portfolio with multiple revenue streams, in different countries, across a range of sectors and this de-risks the company massively IMHO. I think that there is a real possibility of a takeover in due course given the barriers to entry by one of the agri giants. It was a steal when I started buying in the late 50s price range. I am confident that we will see a multipound share price over the next 3-5 years. Good luck :) Good decision re BOO - our values and principles are more important than a few pieces of silver !
well multib - didn't realise you were here! Look like sells to me given the times of trade. Hope not - I just getting into profit on these! and thanks for the heads up re boo on that thread - sold out completely - hadnt realised there was a second dispatches on boo - and now watching the programme. Right decision me thinks
Two massive trades - 1m and 600k at 109.50 and bid has moved up....probably buys ? Clearly out of the ordinary !
It's a great ride enjoying this huge profit
Looks way overvalued to me.
Company webinar yesterday which although just running through the annual report probably responsible for todays bounce. Basically reiterated all their positive news. Sold half my holding this morning (bought and been adding since June @62p) - can see it falling back to 90p before next leg up at which point i will buy again. Still a lot further to go in this.
Chat Pages: 21  20  19  18  17  16  15  14  13  12  11  10  Older
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20170923 09:21:51